Junji Kato

Junji Kato

Auto-generated profile, based on publicly available information

Junji Kato

Department of Dermatology Sapporo Medical University School of Medicine Sapporo Japan

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2017 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
MSMasahide Sawada
Masahide Sawada
JKJunji Kato
Junji Kato
TYToshiharu Yamashita
Toshiharu Yamashita
AYAkihiro Yoneta
Akihiro Yoneta
THTokimasa Hida
Tokimasa Hida
HUHisashi Uhara
Hisashi Uhara

1 June 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
KKKeiju Kobayashi
Keiju Kobayashi
RKRyuta Kamekura
Ryuta Kamekura
JKJunji Kato
Junji Kato
SKShiori Kamiya
Shiori Kamiya
TKTakafumi Kamiya
Takafumi Kamiya
HUHisashi Uhara
Hisashi Uhara

4 December 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
TMTomoyuki Minowa
Tomoyuki Minowa
KMKenji Murata
Kenji Murata
YMYuka Mizue
Yuka Mizue
AMAiko Murai
Aiko Murai
MNMunehide Nakatsugawa
Munehide Nakatsugawa
Toshihiko TorigoeToshihiko Torigoe
Toshihiko Torigoe
Acral lentiginous melanoma (ALM) is the most common melanoma subtype in non-Caucasians. Despite advances in cancer immunotherapy, current immune checkpoint inhibitors remain unsatisfactory for ALM. Hence, we conducted comprehensive immune profiling using single-cell phenotyping with reactivity screening of the T cell receptors of tumor-infiltrating T lymphocytes (TILs) in ALM. Compared with cutaneous melanoma, ALM showed a lower frequency of tumor-reactive CD8 clusters and an enrichment of regulatory T cells with direct tumor recognition ability, suggesting a suppressive immune microenvironment in ALM. Tumor-reactive CD8 TILs showed heterogeneous expression of coinhibitory molecules, including KLRC1 (NKG2A), in subpopulations with therapeutic implications. Overall, our study provides a foundation for enhancing the efficacy of immunotherapy in ALM.

16 August 2023 in Cancer Medicine
Verified
Journal Article
Open access
KNKenjiro Namikawa
Kenjiro Namikawa
TITakamichi Ito
Takamichi Ito
SYShusuke Yoshikawa
Shusuke Yoshikawa
KYKoji Yoshino
Koji Yoshino
YKYukiko Kiniwa
Yukiko Kiniwa
NYNaoya Yamazaki
Naoya Yamazaki
Background: Anti‐PD‐1‐based immunotherapy is considered a preferred first‐line treatment for advanced BRAF V600‐mutant melanoma. However, a recent international multi‐center study suggested that the efficacy of immunotherapy is poorer in Asian patients in the non‐acral cutaneous subtype. We hypothesized that the optimal first‐line treatment for Asian patients may be different.Methods: We retrospectively collected data of Asian patients with advanced BRAF V600‐mutant melanoma treated with first‐line BRAF/MEK inhibitors (BRAF/MEKi), anti‐PD‐1 monotherapy (Anti‐PD‐1), and nivolumab plus ipilimumab (PD‐1/CTLA‐4) between 2016 and 2021 from 28 institutions in Japan.Results: We identified 336 patients treated with BRAF/MEKi (n = 236), Anti‐PD‐1 (n = 64) and PD‐1/CTLA‐4 (n = 36). The median follow‐up duration was 19.9 months for all patients and 28.6 months for the 184 pa tients who were alive at their last follow‐up. For patients treated with BRAF/MEKi, anti‐PD‐1, PD‐1/CTLA‐4, the median ages at baseline were 62, 62, and 53 years (p = 0.03); objective response rates were 69%, 27%, and 28% (p < 0.001); median progression‐free survival (PFS) was 14.7, 5.4, and 5.8 months (p = 0.003), and median overall survival (OS) was 34.6, 37.0 months, and not reached, respectively (p = 0.535). In multivariable analysis, hazard ratios (HRs) for PFS of Anti‐PD‐1 and PD‐1/CTLA‐4 compared with BRAF/MEKi were 2.30 (p < 0.001) and 1.38 (p = 0.147), and for OS, HRs were 1.37 (p = 0.111) and 0.56 (p = 0.075), respectively. In propensity‐score matching, BRAF/MEKi showed a tendency for longer PFS and equivalent OS with PD‐1/CTLA‐4 (HRs for PD‐1/CTLA‐4 were 1.78 [p = 0.149]) and 1.03 [p = 0.953], respectively). For patients who received second‐line treatment, BRAF/MEKi followed by PD‐1/CTLA‐4 showed poor survival outcomes.Conclusions: The superiority of PD‐1/CTLA‐4 over BRAF/MEKi appears modest in Asian patients. First‐line BRAF/MEKi remains feasible, but it is difficult to salvage at progression. Ethnicity should be considered when selecting systemic therapies until personalized biomarkers are available in daily practice. Further studies are needed to establish the optimal treatment sequence for Asian patients.

13 February 2019 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
JKJunji Kato
Junji Kato
THTokimasa Hida
Tokimasa Hida
MSMasanori Someya
Masanori Someya
SSSayuri Sato
Sayuri Sato
MSMasahide Sawada
Masahide Sawada
HUHisashi Uhara
Hisashi Uhara

13 June 2008 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
CSC Shimura
C Shimura
Takeshi SarayaTakeshi Saraya
Takeshi Saraya
HWH Wada
H Wada
STS Takata
S Takata
SMS Mikura
S Mikura
HGH Goto
H Goto
A case of Legionella pneumophila pneumonia with rhabdomyolysis-induced acute tubulointerstitial nephritis (ATIN) and prolonged renal dysfunction is presented. The patient was a 54-year-old man, admitted with high-grade fever, ataxia and muscle dysfunction; chest roentgenogram showed multilobular infiltrations. L pneumophila was detected in his sputum and urine, by PCR and by culture, and L pneumophila pneumonia was diagnosed. Despite antimicrobial treatment, he developed renal failure and rhabdomyolysis. Renal biopsy showed the presence of myoglobin casts that occluded the distal tubuli and tubulointerstitial nephritis, leading to the diagnosis of rhabdomyolysis-induced ATIN. Renal function subsequently normalised, and he was discharged. This is believed to be the first pathological evidence of involvement of rhabdomyolysis in legionellosis-associated ATIN.